Cephalon, Inc. (CEPH) and Mesoblast Post Positive Interim Results for Phase 2 Stem Cell Product

QualityStocks would like to highlight Cephalon, Inc. (NASDAQ: CEPH), a biopharmaceutical company engaged in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients.

In the company’s news yesterday,

Biopharmaceutical company Cephalon Inc. and Mesoblast Limited (ASX: MSB), a leading global developer and manufacturer of biologic products, announced positive interim results from Mesoblast’s ongoing multi-center phase 2 trial of its “off-the-shelf” proprietary adult stem cell product Revascor™ for patients with congestive heart failure.

Revascor is an allogeneic cell therapy product designed to reverse congestive heart failure. The product is administered by a minimally invasive cardiac catheterization procedure to damaged areas of the heart; the procedure is performed under local anesthesia while the patient is awake.

According to the phase 2 trial results, patients who received a single injection of Revascor have had less cardiac events, deaths and hospitalizations during the follow-up period to date than control patients.

Mesoblast is evaluating the safety and efficacy of Revascor in a randomized, placebo-controlled phase 2 trial in 60 patients with moderate-severe congestive heart failure. The companies reported that there have been no cell-related adverse events in any of the 45 patients treated with Revascor demonstrating that all three doses of the cell therapy product are safe over both the short and medium term.

Analyses of time-dependent hard efficacy endpoints showed that a single injection of Revascor:

• significantly reduced the number of patients who developed any severe adverse cardiac events over the follow-up period from 93.3 percent in the control group to 44.4 percent in the treated patients;

• significantly reduced the number of patients who developed any major adverse cardiac events (MACE, defined as the composite of cardiac death, heart attack, or coronary revascularization procedures) from 40 percent to 6.7 percent;

• reduced the overall monthly event rate of a MACE by 84 percent compared with controls, and every dose tested demonstrated a similar protective effect.

Death from cardiac causes was reduced from 13.3 percent to 0 percent over this period and the overall monthly rate of cardiac-related hospitalizations was reduced by 48 percent.

“We are very pleased with these interim results that show for the first time that our proprietary technology can impact both quality of life and survival. If these long-term beneficial outcomes from a single dose of our adult stem cells are sustained they will translate into significant improvements to the quality of life and longevity of patients who are struggling with debilitating congestive heart failure,” Mesoblast CEO Professor Silviu Itescu stated in the press release.

Cephalon, CEO J. Kevin Buchi, said the results reflect Cephalon’s support and strategic investment in Mesoblast’s innovative adult stem cell technology platform. Buchi said the company will move forward with the clinical development of Revascor for the treatment of congestive heart failure toward a phase 3/pivotal trial.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.